Peroxisome-Proliferator Receptor γ Represses Hepatic Sex Hormone-Binding Globulin Expression

Plasma SHBG production by the liver is influenced by its metabolic state, and hepatocyte nuclear factor-4 alpha regulates SHBG expression in response to changes in lipogenesis. Peroxisome-proliferator receptors (PPARs) also regulate glucose homeostasis and fatty acid metabolism. The human SHBG promoter contains a PPAR-response element (PPAR-RE), and plasma SHBG levels increase in polycystic ovarian syndrome patients treated with the PPAR gamma agonist, rosiglitazone. In addition, plasma SHBG levels are associated with a genetic polymorphism in the PPAR gamma-2 coding sequence that alters its transcriptional activity. Therefore, we set out to determine whether PPAR gamma influences hepatic production of SHBG by using human HepG2 hepatoblastoma cells as an in vitro model. Surprisingly, treatment of HepG2 cells with rosiglitazone reduced SHBG production and SHBG promoter activity (as assessed in a luciferase reporter gene assay) by 20-25%, whereas the PPAR gamma antagonist, GW9662, increased both by 2- to 3-fold. The effects of PPAR gamma agonists and antagonists on SHBG promoter activity were substantially diminished when the PPAR-RE in the SHBG promoter was mutated. APPAR gamma small interfering RNA also increased SHBG production by HepG2 cells as well as SHBG promoter activity, and the latter was accentuated by cotreatment with GW9662. Importantly, overexpression of a PPAR gamma-2 Pro12 variant in HepG2 cells was more effective at reducing SHBG promoter activity, when compared with PPAR gamma-2 Ala12, consistent with its superior PPAR-RE binding activity. We conclude that PPAR gamma represses human SHBG expression in liver cells, and that differences in PPAR gamma levels and activity contribute directly to variations in plasma SHBG levels. (Endocrinology 150: 2183-2189, 2009)